AstraZeneca Results Presentation Deck
32 Jesse living with gMG
Bunny ving with PNH
658
Aira living with HPP
Justice living with aHUS
1
Soliris
PNH, aHUS, gMG, NMOSD
●
●
Rare Disease
Q3 2021¹ performance highlights leading C5 franchise
●
Global $798m, (-2%)
US (+4%),
EU (-3%),
EM (-40%),
EROW (+10%)
Strong volume
growth in Neurology,
offset by successful
conversion to
Ultomiris and prior
year EM tender
market order timing
• Global $297m, (+31%)
●
●
Ultomiris
PNH, aHUS
●
US (+25%),
EU (+77%),
EM (n/m),
EROW (+5%)
Performance driven by
strong conversion from
Soliris, and 14 new
country launches this
year
Strensiq
HPP
Global $159m, (+8%)
US (+6%),
EU (+5%),
EM (+75%),
EROW (+11%)
Strong underlying
volume growth in US
gMG = generalised myasthenia gravis; NMOSD = neuromyelitis optica spectrum disorder; HPP = hypophosphatasia. 1. Q3 2021 revenues from date of acquisition closing,
21 July 2021 through 30 September 2021; pro-forma growth rates calculated by comparing post-acquisition revenues with the corresponding prior year Q3 revenues
adjusted pro-rata to match the post-acquisition period.View entire presentation